Tag: Drug Repurposing Market Share

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Drug Repurposing Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The drug repurposing market has experienced substantial growth in recent years. It will grow from $37.38 billion in 2025 to $40.95 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. This historical expansion can be attributed to several factors, including the significant cost and time involved in traditional drug discovery, an increasing number of failed drug candidates, the rising incidence of chronic and rare diseases, a scarcity of therapeutic options for emerging diseases, and the early integration of computational approaches for drug repositioning.

The drug repurposing market size is expected to show robust expansion in the near future. It is projected to increase to $58.33 billion in 2030, driven by a compound annual growth rate (CAGR) of 9.2%. This projected growth can be attributed to the integration of AI and machine learning in drug repurposing, a surge in investment within biotech and pharma research, the expanding capabilities of contract research organizations (CROs), an increasing demand for affordable therapies, and supportive regulatory environments for repurposed drug approvals. Significant developments anticipated during this forecast period include an intensified focus on phenotypic and target-based screening, the rising adoption of structure-based drug repositioning, advancements in identifying off-target activities, the extended application of drug repurposing for rare and infectious diseases, and the shortening of drug development timelines through the utilization of existing molecules.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=51121206&type=smp&name=Drug%20Repurposing%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Drug Repurposing Market Growth Factors Behind Sustained Expansion

The rising incidence of neurodegenerative diseases is anticipated to boost the expansion of the drug repurposing market in the future. Neurodegenerative diseases represent a collection of disorders characterized by the progressive loss of structure or function in neurons, eventually resulting in their death. The increase in neurodegenerative conditions, such as alzheimer’s dementia, is attributed to extended life expectancy, as aging is the primary risk factor contributing to the gradual decline of neuronal function over time. Drug repurposing assists in combating neurodegenerative diseases by identifying existing drugs with established safety profiles that can be re-directed to target specific disease pathways, thereby accelerating the development of effective treatments. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with forecasts indicating an increase to 13.8 million by 2060. Therefore, the growing prevalence of neurodegenerative diseases is a key driver for the growth of the drug repurposing market.

Drug Repurposing Market Breakdown By Product Type And Application

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

Drug Repurposing Market Industry Trends Fueling Future Revenue Growth

Leading firms within the drug repurposing market are concentrating on creating sophisticated technologies, specifically artificial intelligence (AI)-powered drug-protein interaction modeling, to speed up the discovery of novel therapeutic applications for existing medications. This particular modeling approach, driven by AI, utilizes artificial intelligence and machine learning to forecast drug interactions with proteins throughout the human proteome, employing vast datasets to improve both precision and reliability. An example of this is Cosmos Health Inc., a US-based healthcare company, which introduced Cloudscreen 2.0, an advanced AI platform for drug repurposing, in July 2025. This system represents a new generation, built to handle datasets more than 100 times larger than previous versions, facilitating a thorough analysis of drug-protein interactions. The platform incorporates mutagenesis data and tools for examining disordered proteins, allowing it to target conditions like cancer, obesity, and diabetes. Furthermore, scalable processing is enabled by graphics processing unit (GPU)-based cloud computing, establishing the platform as a vital advancement in speeding up research and development for drug repurposing across diverse therapeutic fields.

Drug Repurposing Market Company Landscape And Competitive Strategy

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

View The Full Drug Repurposing Market Report:

https://thebusinessresearchcompany.com/report/drug-repurposing-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Drug Repurposing Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Drug Repurposing Market Growth From $40.95 Billion In 2026 To $58.33 Billion By 2030 At A CAGR Of 9.2%

The drug repurposing market has experienced robust expansion over recent years. Its value is projected to rise from $37.38 billion in 2025 to $40.95 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.6%. This historical growth has been fueled by several factors, including the substantial expenses and time required for conventional drug discovery, a growing volume of unsuccessful drug candidates, a higher incidence of chronic and rare conditions, scarce therapeutic alternatives for new diseases, and the early integration of computational approaches for drug repositioning.

The market for drug repurposing is projected to experience robust expansion over the coming years, reaching an estimated $58.33 billion by 2030, representing a compound annual growth rate (CAGR) of 9.2%. This forecasted growth is driven by several key factors, including the integration of artificial intelligence and machine learning into repurposing efforts, heightened investment in biotechnology and pharmaceutical research, the broadening capabilities of contract research organizations (CROs), increased demand for cost-effective treatment options, and favorable regulatory frameworks for approving repurposed medications. Prominent trends shaping this period involve a stronger emphasis on phenotypic and target-based screening methods, a rising preference for structure-based drug repositioning, advancements in identifying off-target activities, the expansion of repurposing applications to rare and infectious diseases, and the acceleration of development timelines by leveraging existing compounds.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Drug Repurposing Market Industry Drivers: What Is Driving Revenue Growth?

The increasing occurrence of neurodegenerative conditions is set to boost the expansion of the drug repurposing market in the coming years. Neurodegenerative diseases encompass a category of conditions marked by the gradual deterioration and eventual death of neurons, leading to a loss of structure or function. A rising number of cases, including Alzheimer’s dementia, stems from extended life expectancy, as aging stands out as the primary risk factor responsible for the progressive decline in neuronal activity over time. Drug repurposing aids in managing these diseases by leveraging existing medications with well-established safety records, which can be repurposed to address specific disease mechanisms, thereby speeding up the development of viable therapies. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with forecasts predicting this number will rise to 13.8 million by 2060. Thus, the growing prevalence of neurodegenerative diseases is fueling the growth of the drug repurposing market.

Drug Repurposing Market Segment Landscape And Growth Potential

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

Drug Repurposing Market Growth Trends: What Is Influencing The Future Outlook?

Key players in the drug repurposing market are increasingly investing in the development of sophisticated technologies, such as artificial intelligence-driven drug-protein interaction models, to expedite the discovery of new therapeutic applications for existing medications. This approach applies machine learning and AI techniques to forecast how drugs bind to proteins throughout the human proteome, utilizing extensive datasets to boost both predictive precision and reliability. A notable example occurred in July 2025, when Cosmos Health Inc., a healthcare firm headquartered in the United States, launched Cloudscreen 2.0, an advanced AI system tailored for drug repurposing. This next-generation tool can process datasets more than 100 times larger than its predecessor, facilitating thorough exploration of drug-protein interactions. By integrating mutagenesis information and capabilities for studying disordered proteins, the platform targets key diseases like cancer, obesity, and diabetes. Furthermore, the use of GPU-based cloud computing enables scalable data processing, positioning this platform as a pivotal advancement in speeding up research and development efforts for drug repurposing across a wide range of therapeutic fields.

Drug Repurposing Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Access The Complete Drug Repurposing Market Report:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Drug Repurposing Market Regional Outlook: Where Are The Largest Opportunities Located?

North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Drug Repurposing Market Progress Between 2026 And 2030?

The drug repurposing market has experienced substantial growth in recent years. It is projected to expand from $37.38 billion in 2025 to $40.95 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.6%. The historical expansion of this market can be attributed to several factors, including the significant cost and time involved in traditional drug discovery, a rising number of failed drug candidates, the increasing prevalence of chronic and rare diseases, limited therapeutic options for emerging diseases, and the early adoption of computational methods for drug repositioning.

The drug repurposing market is anticipated to experience robust expansion over the coming years, projected to reach $58.33 billion by 2030, driven by a compound annual growth rate (CAGR) of 9.2%. This growth throughout the forecast period stems from factors such as the integration of AI and machine learning in drug repurposing, increasing investment in biotech and pharmaceutical research, the broadening capabilities of contract research organizations (CROs), a heightened demand for cost-effective therapies, and supportive regulatory frameworks for repurposed drug approvals. Key trends expected during this period involve a greater emphasis on phenotypic and target-based screening, the growing acceptance of structure-based drug repositioning, the development of off-target activity identification methods, the wider application of drug repurposing for rare and infectious diseases, and the reduction of drug development timelines by leveraging existing molecules.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp

Which Drivers Are Supporting The Drug Repurposing Market Growth?

The expanding occurrence of neurodegenerative conditions is anticipated to fuel the expansion of the drug repurposing market in the future. These diseases are a category of ailments marked by the gradual deterioration of neuron structure or function, ultimately leading to their demise. The surge in neurodegenerative conditions, for instance, Alzheimer’s dementia, stems from longer life expectancies, given that aging serves as the main risk factor for the progressive decline of neuronal activity over time. Drug repurposing aids in addressing neurodegenerative diseases by pinpointing established medications with verified safety records that can be re-purposed to target specific disease mechanisms, thereby expediting the creation of efficacious therapies. As an illustration, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with forecasts predicting a rise to 13.8 million by 2060. Consequently, the increasing occurrence of neurodegenerative disorders is propelling the expansion of the drug repurposing market.

How Are Segments Identified Within The Drug Repurposing Market Segment Framework?

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

Which Trends Are Contributing To Changes In The Drug Repurposing Market?

Key players within the drug repurposing sector are prioritizing the creation of sophisticated tools, including artificial intelligence (AI)-driven drug-protein interaction modeling, to hasten the discovery of novel therapeutic applications for existing medications. This AI-enabled drug-protein interaction modeling utilizes AI and machine learning capabilities to forecast drug interactions with proteins throughout the human proteome, employing vast datasets to boost both precision and reliability. For example, in July 2025, Cosmos Health Inc., a US-based healthcare firm, launched Cloudscreen 2.0, an advanced AI platform specifically for drug repurposing initiatives. The system represents a next-generation design, capable of processing datasets more than 100 times larger than previous versions, which allows for thorough analysis of drug-protein interactions. Incorporating mutagenesis data and specific tools for assessing disordered proteins, this platform is geared towards addressing diseases like cancer, obesity, and diabetes. Moreover, its foundation in graphics processing unit (GPU)-based cloud computing facilitates scalable processing, establishing the platform as a pivotal innovation for accelerating research and development pipelines in drug repurposing across numerous therapeutic fields.

Who Are The Companies Competing Within The Drug Repurposing Market?

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Get The Full Drug Repurposing Market Report:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

Which Geographic Region Dominates The Drug Repurposing Market?

North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Drug Repurposing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

Browse Through More Reports Similar to the Global Drug Repurposing Market 2026, By The Business Research Company

Pharmacy Repackaging Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-repackaging-systems-global-market-report

Music Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Personal Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/personal-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Drug Repurposing Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The scale of the drug repurposing market has experienced significant expansion recently. This market is projected to expand from $37.38 billion in 2025 to reach $40.95 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 9.6%. Historically, this growth can be ascribed to factors such as the considerable expense and duration involved in conventional drug discovery, a rising count of unsuccessful drug candidates, the escalating occurrence of chronic and rare illnesses, restricted treatment choices for new diseases, and the early incorporation of computational approaches for drug repositioning.

The drug repurposing market size is projected to experience significant expansion in the upcoming years. It is anticipated to grow to $58.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.2%. This expected growth is largely attributed to the integration of AI and machine learning in drug repurposing, increasing investment in biotech and pharma research, the expanding capabilities of contract research organizations (CROs), a rising demand for more affordable therapies, and supportive regulatory frameworks for repurposed drug approvals. Throughout the forecast period, major trends are expected to include an intensifying focus on phenotypic and target-based screening, the growing adoption of structure-based drug repositioning, advancements in approaches for identifying off-target activity, the expansion of drug repurposing applications for rare and infectious diseases, and the shortening of drug development timelines by leveraging existing molecules.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Drug Repurposing Market?

The increasing occurrence of neurodegenerative diseases is projected to stimulate the expansion of the drug repurposing market moving forward. These disorders are characterized by a progressive loss of structure or function in neurons, leading to their eventual demise. The surge in neurodegenerative conditions such as Alzheimer’s dementia is attributed to enhanced life expectancy, as aging stands as the primary risk factor contributing to the gradual decline of neuronal function over time. Drug repurposing assists in combating neurodegenerative diseases by identifying existing medications with established safety profiles that can be redirected to target specific disease pathways, thereby accelerating the development of effective treatments. For instance, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that about 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, with projections suggesting an increase to 13.8 million by 2060. Therefore, the growing prevalence of neurodegenerative diseases is a key factor propelling the growth of the drug repurposing market.

What Major Segment Divisions Exist Within The Drug Repurposing Market?

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

How Are Trends Shaping The Direction Of The Drug Repurposing Market?

Major companies operating in the drug repurposing market are prioritizing the creation of advanced technologies, like artificial intelligence (AI)-powered drug-protein interaction modeling, to accelerate the identification of new therapeutic uses for existing drugs. This AI-powered drug-protein interaction modeling leverages artificial intelligence and machine learning to predict how drugs interact with proteins throughout the human proteome, utilizing expansive datasets to enhance accuracy and confidence. As an illustration, in July 2025, Cosmos Health Inc., a US-based healthcare company, unveiled Cloudscreen 2.0, an advanced AI platform designed for drug repurposing. This next-generation system is engineered to process datasets over 100 times larger than before, enabling comprehensive analysis of drug-protein interactions. By incorporating mutagenesis data and tools for analyzing disordered proteins, the platform targets diseases such as cancer, obesity, and diabetes. Additionally, graphics processing unit (GPU)-based cloud computing empowers scalable processing, making the platform a critical innovation in accelerating research and development pipelines for drug repurposing across multiple therapeutic areas.

Which Companies Are Leading Innovation In The Drug Repurposing Market?

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Read the full drug repurposing market report here:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

What Are The Leading Geographic Regions In The Drug Repurposing Market?

North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Drug Repurposing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25758&type=smp

Browse Through More Reports Similar to the Global Drug Repurposing Market 2026, By The Business Research Company

Pharmacy Repackaging Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-repackaging-systems-global-market-report

Music Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Personal Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/personal-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the drug repurposing market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Drug Repurposing Market?

The drug repurposing market has experienced robust expansion in recent times. Projections indicate its size will increase from $37.38 billion in 2025 to $40.95 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. Historically, this growth has been driven by several factors, including the significant expense and lengthy timelines associated with conventional drug discovery, a growing count of unsuccessful drug candidates, the increasing occurrence of chronic and rare diseases, insufficient treatment options for novel diseases, and the prompt integration of computational techniques for drug repositioning.

The drug repurposing market is projected to experience substantial expansion in the coming years, with its size expected to reach $58.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.2%. This anticipated growth during the forecast period is fueled by several factors, including the incorporation of AI and machine learning into drug repurposing, increased investment in biotechnology and pharmaceutical research, the broadening capabilities of contract research organizations (CROs), an escalating need for economical treatments, and favorable regulatory frameworks for repurposed drug approvals. Key trends expected within this period encompass a heightened emphasis on phenotypic and target-based screening methods, the growing acceptance of structure-based drug repositioning, advancements in identifying off-target activities, the extended application of drug repurposing for treating rare and infectious diseases, and the reduction of drug development timelines by utilizing existing molecules.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp

Which Drivers Are Supporting The Rise Of The Drug Repurposing Market?

The increasing incidence of neurodegenerative conditions is anticipated to drive expansion in the drug repurposing market in the future. These diseases encompass a category of ailments marked by the gradual deterioration of neuron structure or function, leading to their demise. The escalation in conditions such as Alzheimer’s dementia is linked to extended life expectancy, given that aging serves as the primary contributing factor to the slow degradation of neuronal activity over time. Drug repurposing aids in addressing neurodegenerative diseases by pinpointing established medications with verified safety records that can be re-channeled to target disease mechanisms, thereby expediting the creation of efficacious therapies. As an illustration, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older are currently afflicted with Alzheimer’s dementia in 2023, with forecasts suggesting this figure will climb to 13.8 million by 2060. Consequently, the expanding occurrence of neurodegenerative conditions is fueling the expansion of the drug repurposing market.

What Segments Are Identified Within The Structure Of The Drug Repurposing Market?

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

Which Innovation Trends Are Advancing Developments Within The Drug Repurposing Market?

Major companies active in the drug repurposing market are concentrating on developing advanced technologies, such as artificial intelligence (AI)-powered drug-protein interaction modeling, to quicken the identification of new treatment uses for current drugs. Artificial intelligence (AI)-powered drug-protein interaction modeling utilizes AI and machine learning to predict how drugs engage with proteins across the entire human proteome, employing vast datasets to improve accuracy and certainty. For example, in July 2025, Cosmos Health Inc., a healthcare company based in the US, introduced Cloudscreen 2.0, an innovative AI platform for drug repurposing. This next-generation system is built to handle datasets over 100 times larger than previous versions, enabling thorough analysis of drug-protein interactions. By integrating mutagenesis data and tools for analyzing disordered proteins, the platform targets illnesses such as cancer, obesity, and diabetes. Furthermore, graphics processing unit (GPU)-based cloud computing facilitates scalable processing, making the platform a crucial advancement in accelerating research and development efforts for drug repurposing across various therapeutic fields.

Which Leading Companies Dominate The Drug Repurposing Market Share?

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

How Does The Drug Repurposing Market Perform Across Major Global Regions?

North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Drug Repurposing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25758&type=smp

Browse Through More Reports Similar to the Global Drug Repurposing Market 2026, By The Business Research Company

Pharmacy Repackaging Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmacy-repackaging-systems-global-market-report

Music Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Personal Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/personal-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Larger Is The Drug Repurposing Market Expected To Become By 2029 Compared With Its 2025 Level?

The drug repurposing market size has experienced substantial growth in recent years. It is anticipated to expand from $34.12 billion in 2024 to $37.38 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.5%. This past growth is primarily due to the escalating cost of novel drug development, an increase in drug failures during clinical trials, a heightened demand for faster drug approval, the growing availability of off-patent drugs, and increased government and academic funding for research.

The market size for drug repurposing is projected to witness significant growth in the upcoming years. It is foreseen to expand to $53.42 billion by 2029, achieving a compound annual growth rate (CAGR) of 9.3%. This projected growth can be ascribed to a rising need for cost-effective therapies, increased financial commitments from pharmaceutical companies, a surge in collaborations among biotech firms, and the broadening of applications within oncology and neurology. Prominent trends throughout the forecast period encompass improvements in computational drug discovery instruments, advanced application of artificial intelligence and machine learning in drug repurposing, novel developments in predictive modeling for drug efficacy, the integration of big data analytics into drug screening, and breakthroughs in biomarker identification.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp

What Are The Top Growth Drivers Impacting The Drug Repurposing Market Outlook?

The increasing occurrence of neurodegenerative diseases is projected to propel the expansion of the drug repurposing market moving forward. These conditions refer to a group of disorders characterized by the gradual deterioration or loss of neuronal structure or function, including their death. The rise in neurodegenerative diseases, such as alzheimer’s dementia, is linked to increased life expectancy, given that aging is the primary risk factor contributing to the progressive decline of neuronal function over time. Drug repurposing aids in combating neurodegenerative diseases by identifying existing medications with known safety profiles that can be redirected to target disease pathways, thereby accelerating the development of effective treatments. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, in 2023, approximately 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, with projections indicating an increase to 13.8 million by 2060. Consequently, the growing prevalence of neurodegenerative diseases is driving the growth of the drug repurposing market.

What Are The Segment Types Shaping The Drug Repurposing Market?

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

Which Competitive Trends Are Defining The Drug Repurposing Market Structure?

Leading companies within the drug repurposing sector are concentrating their efforts on creating sophisticated technologies, like artificial intelligence (AI)-driven drug-protein interaction modeling, aiming to expedite the discovery of novel therapeutic applications for existing medicines. This AI-driven drug-protein interaction modeling utilizes artificial intelligence and machine learning techniques to forecast drug-protein interactions throughout the human proteome, employing extensive datasets to bolster precision and reliability. As an illustration, in July 2025, Cosmos Health Inc., a US-based healthcare firm, launched Cloudscreen 2.0, which is an advanced artificial intelligence platform specifically for drug repurposing. This next-generation system is engineered to handle datasets exceeding 100 times their previous size, facilitating a thorough analysis of drug-protein interactions. Through the integration of mutagenesis data and instruments for examining disordered proteins, the platform addresses conditions like cancer, obesity, and diabetes. Furthermore, graphics processing unit (GPU)-based cloud computing provides scalable processing capabilities, establishing the platform as a vital advancement in speeding up research and development trajectories for drug repurposing across various therapeutic domains.

Who Are The Major Companies Operating In The Drug Repurposing Market?

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , International Business Machines Corporation (IBM), Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Alnylam Pharmaceuticals Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Cosmos Health Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

How Do Regional Market Performances Compare Within The Drug Repurposing Industry?

North America was the largest region in the drug repurposing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Drug Repurposing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25758&type=smp

Browse Through More Reports Similar to the Global Drug Repurposing Market 2025, By The Business Research Company

Pharmacy Repackaging Systems Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmacy-repackaging-systems-global-market-report

Music Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/music-therapy-global-market-report

Personal Development Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/personal-development-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Drug Repurposing Industry?

In recent times, the drug repurposing market has seen impressive growth. The market, which will rise from $34.12 billion in 2024 to $37.38 billion in 2025, is expected to grow at a mammoth compound annual growth rate (CAGR) of 9.5%. The surge in this period is a result of factors such as the increasing expense of developing new drugs, an increase in the number of drug failures during clinical trials, the growing demand for quicker drug approval processes, a rise in the availability of off-patent drugs, and significant increases in government and academic research funding.

In the coming years, substantial growth is anticipated for the drug repurposing market, which is projected to reach $53.42 billion by 2029 at a compound annual growth rate (CAGR) of 9.3%. Factors contributing to this growth in the forecast period include a higher demand for therapies that are cost-effective, increased investment by pharmaceutical companies, growing partnerships between biotech firms, and broader applications in the fields of oncology and neurology. Key trends forecasted for this period include advancements in tools used for computational drug discovery, increased implementation of AI and ML in drug repurposing, innovations in predictive models for drug efficacy, incorporation of big data analytics in drug screening, and progress in the identification of biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25758&type=smp

#Which Factors Are Currently Driving The Growth Of The Drug Repurposing Market?

The escalating occurrence of neurodegenerative diseases is anticipated to boost the expansion of the drug repurposing market in the future. Neurodegenerative diseases encompass a variety of conditions marked by the gradual degeneration or loss of neuronal structure or function, plus eventual neuronal death. The increasing instances of such diseases, like Alzheimer’s dementia, result from higher life expectancy, as age is a significant risk factor causing the steady deterioration of neuronal function over time. Drug repurposing aids patients suffering from neurodegenerative diseases by pinpointing existing medication with established safety profiles that can be rerouted to target disease channels, expediting the creation of efficient treatments. For example, in March 2023, the Alzheimer’s Association, a US-based volunteer health organization, stated that around 6.7 million US citizens aged 65 and older are battling Alzheimer’s dementia, with predictions suggesting this number will rise to 13.8 million by 2060. Hence, the ascendant prevalence of neurodegenerative diseases is fueling the growth of the drug repurposing market.

How Is The Global Drug Repurposing Market Structured In Terms Of Segments?

The drug repurposing market covered in this report is segmented –

1) By Type: Disease-Centric, Target-Centric, Drug-Centric

2) By Drug Molecules: Biologics, Small Molecule

3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders

4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular

5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations

Subsegments:

1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing

2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting

3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing

What Trends Are Currently Influencing Growth In The Drug Repurposing Market?

Leading firms in the drug repurposing sector are honing their focus on the progression of sophisticated technology such as artificial intelligence-led drug-protein interaction modelling. This approach can expedite the discovery of alternative treatment paths for drugs already available in the market. These AI-led models employ expansive datasets, enhancing confidence and accuracy by predicting the interactions of drugs with proteins throughout the human proteome. Illustratively, in July 2025, the US healthcare firm Cosmos Health Inc. brought to the market Cloudscreen 2.0, a cutting-edge AI platform designed for drug repurposing. This progressive system can process datasets that are over 100 times larger than its predecessors, facilitating thorough analysis of drug-protein interactions. By using mutagenesis data and tools for disordered protein analysis, the platform focuses on targeting diseases such as cancer, diabetes, and obesity. Furthermore, with the application of graphics processing unit based cloud computing for scalable processing, the platform is set to be a game-changer in accelerating R&D for drug repurposing across various therapeutic sectors.

Who Are The Main Participants Shaping The Drug Repurposing Market Landscape?

Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , International Business Machines Corporation (IBM), Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Alnylam Pharmaceuticals Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Cosmos Health Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/drug-repurposing-global-market-report

Which Region Currently Holds The Largest Share In The Drug Repurposing Market?

North America was the largest region in the drug repurposing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25758&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model